Just to clarifyHi All, I wish to quickly point out a key technology in MDG's portfolio. One that is very relevant to the ongoing flu crisis. If you read company's profile you will see that one of MDG'S pursuits is a "MEDICAGO's proprietary transient expression system" technology. Company has an excellent way of explaining what this is and how it works, take a minute to read it please:
To face pandemic and seasonal vaccine supply challenges, Medicago has developed a proprietary transient expression system which produces recombinant vaccine antigens in the cells of non-transgenic plants. This technology offers significant advantages of speed and cost over competitive egg-based and cell culture technologies. It can deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from the pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of the pandemic strikes and to supply large volumes of vaccine antigens to the world market including developing countries.
Now, this technology is related but not dependant on their OTHER pursuit of an influenza vaccine which is in the first stage of clinical trials. So for those that may not know enough about vaccines, and i fit this profile as it took me four hours to figure this out, MDG has a technology that anyone can buy and use to build supplies of vaccines....vaccine's genetic sequence is not a secret. this is actually distributed by the WHO, via email believe it or not.
I hope that clarifies a few things. If anything is incorrect in what i've said above please feel free to correct me.
Stay healthy!